Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRL1 | P41146 | 3/20 | 0.56 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | CCR3 | P51677 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.46 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.44 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.44 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2877688 | 0.84 | OPRL1 (0.77) | OPRL1POLBALDH1A1CCR3CYP2D6 | |
| SCHEMBL2360601 | 0.80 | OPRL1 (0.70) | OPRL1POLBALDH1A1CCR3CYP2D6 | |
| SCHEMBL2328504 | 0.80 | OPRL1 (0.70) | OPRL1POLBALDH1A1CCR3CYP2D6 | |
| SCHEMBL17586464 | 0.78 | OPRL1 (0.54) | OPRL1POLBALDH1A1CCR3LMNA | |
| SCHEMBL639574 | 0.76 | OPRL1 (0.73) | OPRL1POLBALDH1A1CCR3LMNA | |
| SCHEMBL350525 | 0.76 | OPRL1 (0.65) | OPRL1POLBALDH1A1CCR3CYP2D6 | |
| SCHEMBL2515120 | 0.76 | OPRL1 (0.56) | OPRL1POLBALDH1A1CCR3LMNA | |
| SCHEMBL6911078 | 0.75 | OPRL1 (0.71) | OPRL1POLBALDH1A1CCR3CYP2D6 | |
| SCHEMBL2323985 | 0.74 | OPRL1 (0.73) | OPRL1POLBALDH1A1CCR3CYP2D6 | |
| SCHEMBL11195174 | 0.73 | OPRL1 (0.77) | OPRL1POLBALDH1A1CCR3CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8044202-B2 | e.g.1'-[(6-chloro-1H-indol-3-yl)carbonyl]-7H-spiro[pentane[3,4-b]pyridine-5,4'-piperidine]; vasopressin V1a receptor antagonist; antidepressant and anxiolytic agent; dysmenorrhea, hypertension, chronic heart failure, inappropriate secretion of vasopressin, liver cirrhosis, nephrotic syndrome | HOFFMANN-LA ROCHE INC. (US) | 2011-10-25 | — | — | US | disclosed |
| US-8044202-B2 | e.g.1'-[(6-chloro-1H-indol-3-yl)carbonyl]-7H-spiro[pentane[3,4-b]pyridine-5,4'-piperidine]; vasopressin V1a receptor antagonist; antidepressant and anxiolytic agent; dysmenorrhea, hypertension, chronic heart failure, inappropriate secretion of vasopressin, liver cirrhosis, nephrotic syndrome | HOFFMANN-LA ROCHE INC. (US) | 2011-10-25 | — | — | US | disclosed |
| US-8044202-B2 | e.g.1'-[(6-chloro-1H-indol-3-yl)carbonyl]-7H-spiro[pentane[3,4-b]pyridine-5,4'-piperidine]; vasopressin V1a receptor antagonist; antidepressant and anxiolytic agent; dysmenorrhea, hypertension, chronic heart failure, inappropriate secretion of vasopressin, liver cirrhosis, nephrotic syndrome | HOFFMANN-LA ROCHE INC. (US) | 2011-10-25 | — | — | US | disclosed |
| US-8039624-B2 | Vasopressin receptor antagonist; antidepressants; anxiolytic agents; dysmemorrhea; hypotensive agents;obsessive complusive disorder; cirrhosis; nephrotic syndrome | HOFFMAN-LA ROCHE INC. (US) | 2011-10-18 | — | — | US | disclosed |
| US-8039624-B2 | Vasopressin receptor antagonist; antidepressants; anxiolytic agents; dysmemorrhea; hypotensive agents;obsessive complusive disorder; cirrhosis; nephrotic syndrome | HOFFMAN-LA ROCHE INC. (US) | 2011-10-18 | — | — | US | disclosed |
| US-8039624-B2 | Vasopressin receptor antagonist; antidepressants; anxiolytic agents; dysmemorrhea; hypotensive agents;obsessive complusive disorder; cirrhosis; nephrotic syndrome | HOFFMAN-LA ROCHE INC. (US) | 2011-10-18 | — | — | US | disclosed |
| US-8034937-B2 | e.g.1'-[(6-chloro-1H-indol-3-yl)carbonyl]-7H-spiro[furo[3,4-b]pyridine-5,4'-piperidine]; vasopressin V1a receptor antagonist; antidepressant and anxiolytic agent; dysmenorrhea, hypertension, chronic heart failure, inappropriate secretion of vasopressin, liver cirrhosis, nephrotic syndrome | HOFFMANN-LA ROCHE INC. (US) | 2011-10-11 | — | — | US | disclosed |
| US-8034937-B2 | e.g.1'-[(6-chloro-1H-indol-3-yl)carbonyl]-7H-spiro[furo[3,4-b]pyridine-5,4'-piperidine]; vasopressin V1a receptor antagonist; antidepressant and anxiolytic agent; dysmenorrhea, hypertension, chronic heart failure, inappropriate secretion of vasopressin, liver cirrhosis, nephrotic syndrome | HOFFMANN-LA ROCHE INC. (US) | 2011-10-11 | — | — | US | disclosed |
| US-8034937-B2 | e.g.1'-[(6-chloro-1H-indol-3-yl)carbonyl]-7H-spiro[furo[3,4-b]pyridine-5,4'-piperidine]; vasopressin V1a receptor antagonist; antidepressant and anxiolytic agent; dysmenorrhea, hypertension, chronic heart failure, inappropriate secretion of vasopressin, liver cirrhosis, nephrotic syndrome | HOFFMANN-LA ROCHE INC. (US) | 2011-10-11 | — | — | US | disclosed |
| EP-2125827-B1 | AZASPIRO DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2010-11-03 | — | — | EP | disclosed |
| US-20080281103-A1 | AZASPIRO DERIVATIVES | F. HOFFMANN-LA ROCHE AG, A SWISS COMPANY (CH) | 2008-11-13 | — | — | US | disclosed |
| US-20080281103-A1 | AZASPIRO DERIVATIVES | F. HOFFMANN-LA ROCHE AG, A SWISS COMPANY (CH) | 2008-11-13 | — | — | US | disclosed |
| US-20080281103-A1 | AZASPIRO DERIVATIVES | F. HOFFMANN-LA ROCHE AG, A SWISS COMPANY (CH) | 2008-11-13 | — | — | US | disclosed |
| WO-2008080844-A1 | AZASPIRO DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2008-07-10 | — | — | WO | disclosed |
| US-20080161333-A1 | AZASPIRO DERIVATIVES | HOFFMANN-LA ROCHE, INC. | 2008-07-03 | — | — | US | disclosed |
| US-20080161333-A1 | AZASPIRO DERIVATIVES | HOFFMANN-LA ROCHE, INC. | 2008-07-03 | — | — | US | disclosed |
| US-20080161333-A1 | AZASPIRO DERIVATIVES | HOFFMANN-LA ROCHE, INC. | 2008-07-03 | — | — | US | disclosed |
| US-20080161332-A1 | AZASPIRO DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2008-07-03 | — | — | US | disclosed |
| US-20080161332-A1 | AZASPIRO DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2008-07-03 | — | — | US | disclosed |
| US-20080161332-A1 | AZASPIRO DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2008-07-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080281103-A1 | AZASPIRO DERIVATIVES | AVPR1A, HTR5A, HTR1A | OPRL1 131/4885POLB 3468/4885ALDH1A1 516/4885 |
| US-20080161332-A1 | AZASPIRO DERIVATIVES | AVPR1A, HTR5A, HTR1A | OPRL1 131/4885POLB 3468/4885ALDH1A1 516/4885 |
| US-20080161333-A1 | AZASPIRO DERIVATIVES | AVPR1A, HTR5A, HTR1A | OPRL1 131/4885POLB 3468/4885ALDH1A1 516/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.